Selvita to Present at Biotech Showcase 2019 in San Francisco

Wednesday, January 2, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

KRAKOW, Poland, January 2, 2019 /PRNewswire/ --

Selvita

(WSE: SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that Chief Executive Officer Pawel Przewiezlikowski will present a corporate overview at the
Biotech Showcase 2019 conference taking place Jan. 7-9 in San Francisco.

Details of the presentation are as follows: 

Date: Monday, January 7, 2019 Time: 4:30 p.m. PST Room: Franciscan A (Ballroom Level) Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street

About Biotech Showcase 

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

To contact Selvita's delegates at this conference, please contact us at: magdalena.marciniak@selvita.com , or +48-539-939-584.

About Selvita 

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.

Contact: 

Julia Balanova (investors) +1-646-378-2936 jbalanova@troutgroup.com

Rich Allan (media) +1-646-378-2958 rallan@troutgroup.com

SOURCE Selvita



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store